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Causes of severe pneumonia requiring hospital admission 
in children without HIV infection from Africa and Asia: 
the PERCH multi-country case-control study
The Pneumonia Etiology Research for Child Health (PERCH) Study Group*
Summary
Background Pneumonia is the leading cause of death among children younger than 5 years. In this study, we estimated 
causes of pneumonia in young African and Asian children, using novel analytical methods applied to clinical and 
microbiological findings.
Methods We did a multi-site, international case-control study in nine study sites in seven countries: Bangladesh, The 
Gambia, Kenya, Mali, South Africa, Thailand, and Zambia. All sites enrolled in the study for 24 months. Cases were 
children aged 1–59 months admitted to hospital with severe pneumonia. Controls were age-group-matched children 
randomly selected from communities surrounding study sites. Nasopharyngeal and oropharyngeal (NP-OP), urine, 
blood, induced sputum, lung aspirate, pleural fluid, and gastric aspirates were tested with cultures, multiplex PCR, or 
both. Primary analyses were restricted to cases without HIV infection and with abnormal chest x-rays and to controls 
without HIV infection. We applied a Bayesian, partial latent class analysis to estimate probabilities of aetiological 
agents at the individual and population level, incorporating case and control data.
Findings Between Aug 15, 2011, and Jan 30, 2014, we enrolled 4232 cases and 5119 community controls. The primary 
analysis group was comprised of 1769 (41·8% of 4232) cases without HIV infection and with positive chest x-rays and 
5102 (99·7% of 5119) community controls without HIV infection. Wheezing was present in 555 (31·7%) of 1752 cases 
(range by site 10·6–97·3%). 30-day case-fatality ratio was 6·4% (114 of 1769 cases). Blood cultures were positive in 
56 (3·2%) of 1749 cases, and Streptococcus pneumoniae was the most common bacteria isolated (19 [33·9%] of 56). 
Almost all cases (98·9%) and controls (98·0%) had at least one pathogen detected by PCR in the NP-OP specimen. 
The detection of respiratory syncytial virus (RSV), parainfluenza virus, human metapneumovirus, influenza virus, 
S pneumoniae, Haemophilus influenzae type b (Hib), H influenzae non-type b, and Pneumocystis jirovecii in NP-OP 
specimens was associated with case status. The aetiology analysis estimated that viruses accounted for 61·4% 
(95% credible interval [CrI] 57·3–65·6) of causes, whereas bacteria accounted for 27·3% (23·3–31·6) and 
Mycobacterium tuberculosis for 5·9% (3·9–8·3). Viruses were less common (54·5%, 95% CrI 47·4–61·5 vs 68·0%, 
62·7–72·7) and bacteria more common (33·7%, 27·2–40·8 vs 22·8%, 18·3–27·6) in very severe pneumonia cases than 
in severe cases. RSV had the greatest aetiological fraction (31·1%, 95% CrI 28·4–34·2) of all pathogens. Human 
rhinovirus, human metapneumovirus A or B, human parainfluenza virus, S pneumoniae, M tuberculosis, and H influenzae 
each accounted for 5% or more of the aetiological distribution. We observed differences in aetiological fraction by 
age for Bordetella pertussis, parainfluenza types 1 and 3, parechovirus–enterovirus, P jirovecii, RSV, rhinovirus, 
Staphylococcus aureus, and S pneumoniae, and differences by severity for RSV, S aureus, S pneumoniae, and parainfluenza 
type 3. The leading ten pathogens of each site accounted for 79% or more of the site’s aetiological fraction.
Interpretation In our study, a small set of pathogens accounted for most cases of pneumonia requiring hospital 
admission. Preventing and treating a subset of pathogens could substantially affect childhood pneumonia outcomes.
Funding Bill & Melinda Gates Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Pneumonia remains the greatest cause of death globally 
in children younger than 5 years, accounting for an 
estimated 12·8% of annual deaths beyond the neonatal 
period.1 A substantial reduction in the past few decades 
of estimated pneumonia deaths (0·9 million in 2015 vs 
1·7 million deaths in 1990) reflects not only economic 
development, improved nutrition, and reduced house­
hold crowding, but also the use of pneumonia­specific 
interventions such as improved case management—
including empirical antibiotic treatment—and effective 
vaccines against leading pneumonia pathogens.2,3 Despite 
these advances, continued progress to reduce pneumonia 
mortality is constrained by the absence of vaccines against 
the remaining common pathogens.
The Pneumonia Etiology Research for Child Health 
(PERCH) study sought to characterise the causes of severe 
childhood pneumonia requiring hospital admission 
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among children living in high­burden, low­resource 
regions in the era of routine use of vaccines against 
pertussis, selected pneumococcal serotypes, Haemophilus 
influenzae type b (Hib), and measles.4 The PERCH study 
sought to provide rigorous data that would inform future 
prevention and treatment strategies in low­income and 
lower­middle­income settings and to address challenges 
faced by previous pneumonia aetiology studies, such as 
imperfect standardisation of methods and analyses, 
narrow generalisability, and absence of an analytical 
method to provide their primary output of interest, an 
aetiological distribution.5,6
Here, we report the descriptive clinical and micro bi­
ological findings of the PERCH study using a traditional 
analytical approach, so that results can be compared 
with those of other pneumonia studies. Acknowledging 
that aetiology cannot be inferred from these results 
alone, we also developed a new analytical approach to 
assess the aetiological distribution of pneumonia.7–9 This 
approach integrates microbiology results from multiple 
specimens types and multiple results for one pathogen 
from an individual; this approach also accounts for the 
sensitivity and specificity of the individual diagnostic 
tests used. We report the probability distributions of the 
microbial aetiology in the study population, and in 
individual cases.
Methods
Study design and participants
The PERCH case­control study design has been previously 
described.4,10,11 Briefly, we assessed the causes of WHO­
defined12 severe or very severe pneumonia (pre­2013 
definitions, originally presented in 2005) among children 
aged 1–59 months presented and admitted to a hospital 
with this condition. The nine study locations in seven 
countries (Basse, The Gambia; Bamako, Mali; Lusaka, 
Zambia; Soweto, South Africa; Kilifi, Kenya; Dhaka and 
Matlab, Bangladesh; and Nakhon Phanom and Sa Kaeo, 
Research in context
Evidence before this study
Before designing and doing the PERCH study, we did a detailed 
review to assess the body of evidence on pneumonia aetiology 
and the epidemiological, laboratory, and analytical methods 
used to quantify causes of pneumonia in young children. 
Additionally, we established an expert panel, the Pneumonia 
Methods Working Group (PMWG), to provide additional advice 
on the key epidemiological, laboratory, study design, 
and analytical issues that the PERCH study needed to optimise. 
The search dates, databases used, search terms, and restrictions 
are detailed in a separate publication (Zunera Gilani and 
colleagues, 2012). The results of our reviews of the pre-existing 
evidence and the decisions reached by the PMWG have been 
published in a set of methods papers and in the protocol. 
Since this review, the descriptive results of three large paediatric 
pneumonia aetiology studies in children younger than 5 years 
have been published—from the USA (EPIC), South Africa 
(Drakenstein), and a multicountry study (GABRIEL)—and were 
considered in our analysis.
Added value of this study
The PERCH study is a comprehensive, systematic, multisite 
study of the causes of severe and very severe pneumonia with 
hospital admission among children aged 1–59 months in the 
context of routine use of Haemophilus influenzae type b and 
pneumococcal conjugate vaccine. The emphasis on a 
single protocol with highly standardised implementation and 
quality control steps throughout the study conduct, the 
inclusion of diverse sites but with routine implementation of 
existing pneumonia vaccines, the duration of enrolment to 
capture seasonal trends, the use of a 33-target multiplex 
quantitative PCR, the inclusion of multiple body fluid specimens, 
the inclusion of an appropriate control group, the adjustment 
for the sensitivity of the laboratory tests, and the large size of 
the study all provided strength to the inferential value of the 
results. Our study provides results for over 30 pathogens and 
allows for cross-site comparisons of aetiological distribution 
because of its highly standardised methodology. It is the 
first infectious aetiology study to integrate the results of testing 
of multiple pathogens from multiple body fluid specimens, by 
using a range of laboratory assays, and to provide an aetiological 
distribution of the pathogens, with uncertainty intervals, 
both by individual and in the population. Our results showed 
that ten pathogens were responsible for 79–90% of cases with 
severe pneumonia requiring hospital admission in children 
younger than 5 years across a wide range of geographical and 
epidemiological settings. Causes of pneumonia varied by age 
strata and severity status and, to a lesser degree, by geography.
Implications of all the available evidence
From a policy perspective, the low number of pathogens that 
are common causes of pneumonia requiring hospital 
admission in children younger than 5 years across all sites could 
allow for targeted development of pneumonia interventions. 
Respiratory syncytial virus was the most common cause of 
disease and should be a primary target for dedicated 
prevention and treatment efforts, especially for children 
younger than 6 months. Bacterial pathogens, cumulatively, 
caused a substantial proportion of disease and, being treatable 
and commonly fatal, should remain a target for early access to 
treatment. Our study clearly shows that the inferential value of 
nasopharyngeal specimens varies by pathogen, with only a low 
number of pathogens providing evidence of causality. 
The PERCH Integrated Analysis shows the value of analytical 
approaches that account for pathogen prevalence, test 
performance, multiple specimens, and multiple results for an 
individual pathogen. The methods developed by the PERCH 
study for integrating such data, in a principled approach, offer 
the opportunity for other aetiology studies to also adapt and 
use these methods.
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Thailand) were selected to represent diverse epi­
demiological conditions through an open call for 
applications.4 Site characteristics, vacci nation schedules for 
each country, and screening and enrolment procedures are 
described in the appendix.4 All sites, except those in 
Thailand, were routinely using Hib vaccine; pneumococcal 
conjugate vaccine (PCV) was in routine use in The 
Gambia, Kenya, Mali, and South Africa and was in routine 
use in Zambia for the last few months of the PERCH 
study. Influenza vaccine was not in routine use at any site.
Cases were enrolled at the time of presentation to the 
hospital. Severe pneumonia was defined as cough or 
difficulty breathing with lower chest wall indrawing; 
very severe pneumonia was defined as cough or difficulty 
breathing and at least one of the following signs: central 
cyanosis, difficulty breastfeeding or drinking, vomiting 
everything, convulsions, lethargy, unconsciousness, or 
head nodding.12 Elevated respiratory rate was not part of 
case definitions (appendix). Exclusion criteria for cases 
and controls were hospitalisation within the preceding 
14 days, having been discharged as a PERCH case within 
the preceding 30 days, and residence outside the study 
catchment area. Cases had the additional exclusion 
criterion of resolution of lower chest wall indrawing after 
bronchodilator therapy for children with wheeze. At all 
sites, case assessment occurred within 24 h of admission. 
In Bangladesh, children from the Dhaka site that met the 
case definition were identified at an outpatient clinic and 
referred for hospital admission; children whose parents 
refused hospital admission were still enrolled if they met 
all other inclusion criteria (n=33). Each site enrolled 
participants over a 24­month period (appendix). Case 
screening was done 24 h per day and 7 days per week at 
four sites (Kilifi, Sa Kaeo, Nakhon Phanom, and Matlab), 
during which all eligible consenting cases were enrolled. 
At the remaining sites, screening was done during 
established hours; all eligible consenting cases presenting 
during predefined screening hours were enrolled, except 
for Mali, where a systematic sampling process was used 
(appendix).
Controls were randomly selected from residents of the 
same catchment area as cases and frequency matched to 
cases by age group (1 to <6 months, 6 to <12 months, 
12 to <24 months, and 24–59 months of age), as previously 
described.11 Sites aimed to enrol a minimum of 25 con­
trols monthly or matched to case counts when they had 
enrolled more than 25 cases in a month. Controls were 
enrolled regardless of respiratory symptoms to provide 
the least biased comparison for estimating pneumonia 
causes, but were ineligible if they met the PERCH case 
definition.11,13
All enrolled children were tested for HIV, except those 
in Bangladesh and controls in The Gambia and Thailand, 
because these were low HIV­prevalence settings. HIV­
positive controls were oversampled in sites with high 
HIV prevalence (Zambia and South Africa) by recruitment 
at HIV treatment clinics.11
The study protocol was approved by the Institutional 
Review Boards or Ethical Review Committees for each of 
the seven institutions and at The Johns Hopkins School 
of Public Health.14 Parents or guardians of participants 
provided written informed consent. We followed stan­
dardised procedures for assessment of enrolment 
criteria, clinical assessment, specimen collection, data 
collection, and laboratory testing.10,15–17 The study protocol, 
data collection forms, standard operating procedures, 
and clinical training videos are publicly available.18
Procedures
Cases underwent clinical examination at admission, at 
24 h, and at 48 h (if the child was still hospitalised) 
including assessments of respiratory signs, anthro­
pomorphic measurements, and peripheral oxygen 
saturation (on room air whenever possible).15,18 We 
assessed the vital status of cases during a follow­up visit 
or telephone interview done 30 days after admission 
(with a window of 21–90 days). Controls were similarly 
assessed for clinical findings at enrolment but had no 
follow­up assessment.18 Clinical definitions used in 
analyses are described in the appendix.
At enrolment, we collected nasopharyngeal and 
oropharyngeal (NP­OP), urine, and blood specimens 
from cases and controls and blood cultures, induced 
sputum, lung aspirate, pleural fluid, and gastric aspirates 
from cases only. Results of bacterial and tuberculosis 
cultures of blood, lung aspirate, and pleural fluid were 
immediately available to the treating physicians. PCR 
results were batched and not available for clinical 
management. Chest x­rays were obtained from cases at 
enrolment and interpreted by two members of the 
PERCH Chest Radiograph Reading Panel trained in the 
WHO method;19 discordant readings were arbitrated as 
described elsewhere.20 Readers were masked to site and 
clinical factors. Chest x­rays were classified as consoli­
dation, other infiltrate, both, normal, or uninterpretable 
by standardised WHO criteria.19–21 We defined x­rays as 
abnormal (positive chest x­ray) if they showed either 
consolidation, other infiltrate, or both.
Specimen collection procedures, laboratory testing 
methods, and determination of pathogen­specific PCR 
density thresholds used in analyses have been described 
separately elsewhere (appendix).17,22–28 Briefly, we used a 
33­pathogen multiplex quantitative PCR (FTD Resp­33, 
Fast Track Diagnostics, Sliema, Malta) and cultures to 
test NP­OP swabs (of cases and controls; cultures were 
done for Streptococcus pneumoniae alone), induced 
sputum (of cases), lung aspirates (of eligible cases in The 
Gambia, Bangladesh, Mali, and South Africa), and 
pleural fluid (at the discretion of the treating paediatrician 
in cases with pleural effusions on chest x­ray); gastric 
aspirates from cases were cultured for mycobacteria 
alone. We tested blood samples for S pneumoniae by PCR 
for cases and controls and with cultures for cases only. 
Pleural fluid specimens that signalled positive by 
See Online for appendix
For the study protocol and 
study materials see https://
www.jhsph.edu/ivac/resources/
perch-background-and-
methods/
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automated culture but yielded no pathogen on subculture 
were also tested for pneumococcal antigen (BinaxNOW, 
Alere, Orlando, FL, USA; appendix). We tested serum 
specimens from cases and controls for the presence of 
antimicrobial activity; specimens from cases were also 
tested for C­reactive protein.
All pathogens detected by blood culture, except for 
contaminants, were included as potential pathogens. We 
excluded PCR results for Klebsiella pneumoniae because of 
poor assay specificity, which was identified after our testing 
protocol was established.29 For Moraxella catarrhalis, 
NP­OP PCR results are described in this study, but were 
excluded from the integrated aetiology analysis; these 
results did not provide useful diagnostic evidence because 
control prevalence of M catarrhalis was substantially 
higher than case prevalence (appendix). We implemented 
confirmatory uniplex PCR testing for specimens that 
tested positive on the multiplex assay for Legionella spp, 
pertussis, and Hib (appendix). For several pathogens with 
similar prevalence in cases and controls (ie, S pneumoniae, 
H influenzae, cytomegalovirus, and P jirovecii from 
NP­OP specimens and S pneumoniae from whole blood 
specimens),24,25,27 positivity was redefined by use of 
quantitative PCR density thresholds based on our 
analyses. For all remaining pathogens, the standard assay 
thresholds were used. Blood culture contaminants were 
defined by standard criteria (appendix) and these results 
were excluded from the aetiology analysis.
We obtained a single induced sputum or gastric aspirate 
specimen from each case, except in South Africa, where 
two specimens were routinely collected for increased 
tuberculosis detection, or at physicians’ discretion for 
cases with suspected tuberculosis diagnosis. The first 
specimen alone was used to define a positive result for 
Mycobacterium tuberculosis to ensure cross­site compa­
rability; the lower sensitivity of a single specimen was 
accounted for in the aetiology analysis. With the exception 
of tuberculosis, we did not use the induced sputum results 
in the aetiology analysis because the microbiological 
findings from sputum culture and PCR did not add 
information beyond that added by the NP­OP specimens, 
which had the analytical advantage of availability from 
both cases and controls.30–32
Pneumococcal serotypes were assessed by Quellung 
reaction or PCR; for NP­OP specimens that were culture 
negative but PCR positive and met the density threshold 
criteria for positivity and adequate specimen volume, we 
used a microarray assay to assess serotype (n=52; 
appendix).17,33 These serotypes were grouped into vaccine­
type or non­vaccine type according to the 13­valent PCV 
(PCV13) formulation. The Gambia, Mali, South Africa, 
and Zambia (for part of the study period) used PCV13, 
whereas Kenya used the ten­valent PCV (PCV10). 
The multiplex PCR panel included a target for all 
H influenzae and for H influenzae type b; cultured isolates 
were serotyped by slide agglutination or PCR. NP­OP 
specimens from cases who met study defined clinical 
criteria for measles (n=33) were tested for measles by 
PCR (appendix). Antibiotic exposure at the time of 
specimen collection was defined as either documented 
admin istration of antibiotics in the facility or antibiotic 
activity in the serum (measured by Staphylococcus aureus 
bioassay), collected at the same time as the specimen.28
Statistical analysis
Data were single­data entered into a centralised electronic 
data capture system (Emmes Corporation, Rockville, 
MD, USA);16 the Kenya site extracted data from its 
existing electronic data capture system, which conformed 
to the study data entry standards.
The number of sites and the number of participants 
enrolled per site were based on a combination of feasibility 
within budget and the case prevalence at each site. Site 
eligibility included, among other criteria, a minimum of 
100 cases per year of severe pneumonia requiring hospital 
admission in children aged 1–59 months. Seven sites 
were selected so that results would represent diverse 
epidemiological settings in Asia and Africa, and sites were 
enrolled for 2 years rather than 1 year to enable asses­
sment of seasonality, annual variations, and outbreaks in 
aetiology.
Unless otherwise specified, we restricted analyses to 
cases and controls without HIV infection because the 
aetiological distribution was expected to vary substantially 
according to HIV infection status (to be reported in a 
separate publication). The primary analysis was to esti­
mate the aetiological fraction of severe and very severe 
pneumonia among cases with a positive chest x­ray; cases 
were restricted to positive results in chest x­rays because 
the analytical method for assessing causes, the PERCH 
Integrated Analysis (PIA) model, assumed that all cases 
had a lung infection. A secondary analysis of all cases 
without HIV infection, regardless of chest x­ray, was done 
and is reported in the appendix.34 Children missing all 
laboratory measurements used in the integrated aetiology 
analysis (blood cultures, NP­OP PCR, whole blood PCR, 
and tuberculosis cultures for cases; NP­OP PCR and 
whole blood PCR for controls) were excluded from the 
analyses. For children with at least one of these measure­
ments, any missing data for the other measurements 
were imputed during model estimation by use of standard 
Bayesian methods.35
Statistical comparisons of demographic and clinical 
characteristics between sites and case­control groups 
were done with logistic regression that adjusted for age in 
months, with or without site as appropriate. We compared 
the prevalence of organisms measured in both cases and 
controls using odds ratios (ORs) with 95% CIs calculated 
by logistic regression, adjusting for site, age in months, 
and the other pathogens detected (this adjustment for 
NP­OP PCR results alone); we could not adjust for 
previous antibiotic use because it was rare among 
controls. Except for selected site­stratified analyses, 
results are for all sites combined; comprehensive 
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site­specific results will be published separately. We used 
elevated C­reactive protein concentrations in the case 
descriptive analysis, but this was not a variable in the PIA 
model.
We developed and used the PIA model, a novel 
application of Bayesian latent class analysis that integrates 
the case and control data across multiple specimens and 
tests, resulting in an estimate of the aetiology distribution 
for each individual case and for the population of 
cases.7–9,36 This method assumes that infections at body 
sites peripheral to the lung are indicative of the cause of 
the putative lung infection and that measurements are 
independent of one another. This method was tested with 
use of simulated datasets comprising cases with known 
aetiology who had a mix of measurements that varied in 
their sensitivity and specificity, which were prespecified, 
and it was shown to give accurate estimates of the 
aetiological fraction, even under mild violations of the 
independence assumption.9 The PIA model uses a 
Markov Chain Monte Carlo algorithm that, on con­
vergence, samples from the posterior distribution of the 
aetiology estimates, given the observed measurements 
(appendix). The population­level estimate for each 
pathogen is the average of the individual case probabilities 
and has a 95% credible interval (95% CrI), the Bayesian 
analogue of the confidence interval. Sensitivity analyses 
were done to assess the influence of the values used for 
aetiology and sensitivity priors (appendix). To allow for 
the possibility that the pneumonia event was caused by a 
pathogen not tested for, we included a pathogen category 
termed not otherwise specified (NOS). Cases who had 
negative tests for all pathogens or positive results only 
in measurements with poor specificity had a higher 
individual­level probability to be included in NOS 
category than other cases.
The PIA model assumes that a pneumonia event is 
caused by a single pathogen. For cases with multiple 
pathogens detected in silver standard measurements 
(eg, blood cultures, lung aspirates, or pleural fluid), the 
model cannot distinguish which one is the dominant 
cause. For these cases, the model distributes the aetiology 
probability equally across the pathogens detected. This 
distribution leads to an underestimation of the contri­
bution of the true cause of the disease because the sum 
of the pathogen probabilities for an individual case in 
this primary pathogen model must be 100%. For cases 
who are negative by silver standard measurements, the 
cause is distributed across multiple pathogens according 
to the strength of evidence for each pathogen. This 
evidence includes whether the pathogen was detected in 
multiple samples from the individual, the pathogen’s 
prevalence among cases, the pathogen’s odds ratio, and 
a­priori assumptions regarding sensitivity and aetiology.
As a Bayesian analysis, we assigned a­priori estimates 
for both the aetiology distribution and the sensitivity of 
each laboratory measurement. These estimates quantify 
the preceding uncertainty about the model parameters. 
The a­priori aetiology distribution favoured no pathogen 
over another (uninformed) because we wanted to 
estimate the causes using the evidence in the PERCH 
study alone. The a­priori sensitivity distribution, selected 
by an internal working group using available information 
external to the PERCH study, varied by laboratory test 
method and pathogen (table 1, appendix). We classified 
specimens according to their estimated measurement 
error as either bronze (ie, imperfect sensitivity and 
specificity) or silver standard (ie, imperfect sensitivity, 
but 100% specificity); no test was categorised as gold 
standard (ie, 100% sensitivity and specificity; table 1, 
a­priori estimates of measurement­specific sensitivity are 
detailed in the appendix).9 Measurements designated as 
silver standard were those of blood cultures, of cultures 
or PCR of percutaneous lung aspirate and pleural fluid 
Base sensitivity 
priors
Reduced 
sensitivity priors
Specificity
Blood cultures*†
Streptococcus pneumoniae 5–20% 1–13% 100%
Haemophilus influenzae 5–20% 1–13% 100%
Moraxella catarrhalis 5–15% 1–10% 100%
Staphylococcus aureus 5–15% 1–10% 100%
Non-fermentative Gram-negative 
rods
5–15% 1–10% 100%
Candida spp 5–15% 1–10% 100%
Non-pneumococcal streptococci, 
including enterococci
5–15% 1–10% 100%
Salmonella spp 10–50% 1–34% 100%
Enterobacteriaceae 10–50% 1–34% 100%
Neisseria meningitidis 10–50% 1–34% 100%
NP-OP PCR
S pneumoniae 50–90%† 15–55% 1–control prevalence‡
H influenzae 50–90%† 15–55% 1–control prevalence‡
Salmonella spp 0·5–90% 0·5–90% 1–control prevalence‡
Legionella spp 0·5–90% 0·5–90% 1–control prevalence‡
All other PCR targets 50–90% 50–90% 1–control prevalence‡
Whole blood PCR
S pneumoniae 12–65% 12–65% 1–control prevalence‡
Induced sputum
Mycobacterium tuberculosis 10–30% 10–30% 100%
Lung aspirate
All pathogens by culture or PCR NA§ NA§ 100%
Pleural fluid
All pathogens by culture or PCR NA§ NA§ 100%
Background information supporting choice of sensitivity priors is provided in the appendix. For base priors, 
specimens had blood culture volume greater than 1·5 mL (blood culture only) and no evidence of previous antibiotic 
exposure; for reduced priors, specimens had blood culture volume lower than 1·5 mL or evidence of previous 
antibiotic exposure. These criteria were not applicable for some pathogen measurements (more details in the 
appendix). NP-OP=nasopharyngeal and oropharyngeal. NA=Not applicable. *Direct evidence of the diagnostic 
sensitivity of blood cultures for S pneumoniae and H influenzae obtained from vaccine probe studies; for all other 
pathogens, we set the base blood culture sensitivity prior to 5–15%, with the exception of Salmonella spp, 
Enterobacteriaceae, and N meningitidis, for which we selected wider priors (10–50%) to reflect their greater 
uncertainty. †Adjusted (reduced) for previous antibiotic exposure and low blood volume (blood culture only; 
see appendix for more details). ‡See appendix for control prevalence. §Results of lung aspirate and pleural fluid were 
used to update the aetiology prior distribution that was applied to cases with similar clinical characteristics.
Table 1: Integrated aetiology analysis input values for sensitivity and specificity of laboratory test measures
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specimens, and of M tuberculosis cultures of induced 
sputum (or gastric aspirate). PCR results from the NP­OP 
swab and whole blood (S pneumoniae alone) specimens 
were included as bronze standard measurements, with 
controls providing the data to estimate specificity. We 
reduced the sensitivity for detecting bacterial pathogens 
in NP­OP PCR (S pneumoniae and H influenzae only) 
and blood culture specimens for individuals whose 
specimens were collected after documented antibiotic 
exposure and for blood culture specimens with low blood 
volume (appendix).
The PIA model integrated the a­priori distributions 
with the observed data, changing (updating) both the 
a­priori distribution and sensitivity estimates with 
contributions of the study data, to produce the aetiology 
estimates.9 The positive lung aspirate results were used to 
update the a­priori aetiology distribution for cases with 
similar chest x­ray characteristics (appendix). Intrinsic 
within the PIA model, the sensitivity of the bronze 
standard measurements (eg, NP­OP) for individual 
bacteria was updated by use of the results of cases with 
positive blood cultures.
A Cases B Community controls||**
5723 eligible children with severe or very severe pneumonia
4232 (73·9%) enrolled
3981 (94·1% of 4232) without 
HIV infection†
1769 (41·8% of 4232) without 
HIV infection CXR-positive†
Laboratory results available
3926 (98·6%) blood cultures  
3910 (98·2%) NP-OP PCR  
3922 (98·5%) pneumococcal NP 
cultures
3757 (94·4%) pneumococcal WB PCR
44 (1·1%) LA cultures‡ 
27 (0·7%) LA PCR‡ 
16 (0·4%) PF cultures‡ 
13 (0·3%) PF PCR‡
3535 (88·8%) tuberculosis IS or GA 
cultures  
30 (0·8%) measles NP-OP PCR§ 
3972 (99·8% of 3981) with ≥1 
laboratory result available¶ 
Laboratory results available
1749 (98·9%) blood cultures  
1733 (98·0%) NP-OP PCR  
1748 (98·8%) pneumococcal NP 
cultures  
1676 (94·7%) pneumococcal WB PCR
41 (2·3%) LA cultures‡ 
27 (1·5%) LA PCR‡
15 (0·8%) PF cultures‡
12 (0·7%) PF PCR‡
 1566 (88.5%) tuberculosis IS or GA 
cultures 
10 (0·7%) measles NP-OP PCR§ 
1767 (99·9% of 1769) with ≥1 
laboratory result available¶
1491 not enrolled
 840 refused
 531 had no legal guardian
 32 died
 88 other*
251 (5·9%) with HIV infection
8994 eligible children contacted††‡‡
5530 (61·5%) screened
3464 declined or did not show to clinic††
5478 (60·9%) eligible
359 refused
5119 (56·9%) enrolled
5102 (99·7% of 5119) without HIV infection†
Laboratory results available
4977 (97·5%) NP-OP PCR
 5043 (98·8%) pneumococcal NP cultures
 4779 (93·7%) pneumococcal WB PCR
5075 (99·5% of 5102) with ≥1 laboratory results available¶
17 (0·3%) with HIV infection**
52 ineligible
 26 admitted to hospital in preceding 14 days
 2 PERCH case in past 30 days
 10 seriously ill and referred to hospital
 1 met case definition
 13 none of the above, not specified
Figure 1: Case (A) and control (B) enrolment and specimen availability profile
CXR=chest x-ray. NP=nasopharyngeal. OP=oropharyngeal. WB=whole blood. LA=lung aspirate. PF=pleural fluid. IS=induced sputum. GA=gastric aspirate. *Of the 
88 children not enrolled because of other reasons, 45 were not enrolled because of an enrolment cap at the Mali site, ten because of political unrest in Bangladesh, 
and 24 in Kenya and nine in Zambia because of reasons not stated. †Included in clinical descriptive analysis. ‡Lung aspirate and pleural fluid specimens were collected 
on a subset of cases eligible for the procedures; for samples with low volumes, only culture was done. §Measles testing was done on a subset of cases who met the 
study defined clinical criteria for measles. ¶Included in laboratory descriptive analysis and aetiology analysis; at least one of the following specimens was required for 
a child to be included in the aetiology analysis: blood culture, NP-OP PCR, WB PCR, or tuberculosis culture for cases; and NP-OP PCR or WB PCR for controls. ||Number 
contacted, screened, and eligible includes some extrapolated data for the Zambia and South Africa sites; data were available for 16 of 24 months for Zambia and 
10·5 of 24 months for South Africa; for each of these sites, available data were used to extrapolate numbers for the months with missing data assuming that contact, 
participation, and eligibility rates were constant over time.**Not shown here are an additional 206 controls with HIV infection enrolled from HIV clinics at the 
South Africa and Zambia sites to ensure adequate sample size of children with HIV infection; these children will be described in forthcoming manuscripts devoted to 
the causes of severe and very severe pneumonia in children with HIV infection. ††Data for total number of children contacted and number of children who declined or 
did not show to clinic were not available for the Mali site. ‡‡Among sites with available data for total number of children contacted (ie, all sites except Mali), 
8149 (73·9%) of 11 033 randomly selected children or households were contacted; the number of children or guardians contacted is used as the denominator for the 
percentage of children screened, eligible, and enrolled; because the denominator excludes Mali but the numerator does not, the percentages for screened, eligible, 
and enrolled are overestimated.
For JAGS see http://mcmc-jags.
sourceforge.net/
For the Bayesian Analysis Kit 
for Etiology Research see 
https://github.com/zhenkewu/
baker
Articles
www.thelancet.com   Published online June 27, 2019   http://dx.doi.org/10.1016/S0140-6736(19)30721-4 7
The PIA model was applied on data from all sites com­
bined and assumed that the measurement sensitivities 
were common across sites, while allowing the aetio­
logical distributions and control prevalences to vary 
across sites (appendix). We did analyses stratified by age 
(<1 year and ≥1 year) and WHO pneumonia severity 
(severe and very severe). The all­site results were based 
on cases with a positive chest x­ray, wherein each case, 
without regard to site, contributed equally to the 
estimated aetiology distribution, and based on all 
controls. To assess differences in the aetiological distri­
bution related to site, we standardised the age and 
severity of case distributions at each site to that of all 
sites combined (appendix). We compared the age 
and severity­standardised results across sites for 
ten focus pathogens (H influenzae, M tuberculosis, 
S aureus, S pneumoniae, human metapneumovirus 
[HMPV], influenza, parainfluenza, rhinovirus, respi­
ratory syncytial virus [RSV], and P jirovecii). We defined 
focus pathogens on the basis of results of the all­site 
aetiological analysis. Focus pathogens were those with 
aetiology estimates higher than 5% (n=7) or higher than 
2% that were of epidemiological interest (defined as 
treatable by antibiotics [P jirovecii and S aureus] or having 
an available vaccine [influenza virus]). The 95% CrI 
around the aetiological fraction of these three pathogens 
overlap with some non­focus pathogens; therefore, we 
used the term focus pathogen rather than labelling these 
ten as the most common pathogens. In this study, we 
also report the list of the site­specific ten most common 
pathogens and the overall aetiological fraction of those 
pathogens (ie, the ten pathogens with the highest 
aetiological fraction at a given site).
We did statistical analyses with SAS, version 9.4, and 
with Bayesian inference software JAGS 4.2.0; NP­OP 
PCR figures were created with R, version 3.3.1. The PIA 
model used an open­source R software package that we 
developed called the Bayesian Analysis Kit for Etiology 
Research.
Role of the funding source
Representatives from the Bill & Melinda Gates Foundation 
participated in site selection and in Pneumonia Methods 
Working Group meetings, which informed the study 
design. They had no role in the data collection, data 
analysis, data interpretation, or writing of the report. The 
corresponding author had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication. 
Results
Between Aug 15, 2011, and Jan 30, 2014, we enrolled 
4232 (73·9%) of 5723 eligible children with severe or 
very severe pneumonia as cases and 5119 (56·9%) of 
8994  eligible children in the study catchment areas 
contacted as community controls; an additional 206 con­
trols with HIV infection were enrolled from HIV clinics 
in South Africa and Zambia for HIV­specific analyses to 
be reported separately (figure 1). Enrolment of cases and 
controls varied by season (appendix). Approximately 
90% of the planned specimens (ranging from 88·8% for 
All cases Cases with a 
positive x-ray
Controls p value
Total 3981 1769 5102 ··
Age, months ·· ·· ·· <0·0001
28 days–5 1619 (40·7%) 691 (39·1%) 1598 (31·3%) ··
6–11 908 (22·8%) 425 (24·0%) 1210 (23·7%) ··
12–23 903 (22·7%) 436 (24·6%) 1262 (24·7%) ··
24–59 551 (13·8%) 217 (12·3%) 1032 (20·2%) ··
Sex
Girls 1684 (42·3%) 778 (44·0%) 2533 (49·7%) <0·0001
Respiratory tract illness (controls 
only)
·· ·· 1206 (23·6%) ··
Positive malaria smear* 91 (3·9%) 19 (1·9%) 35 (1·3%) 0·1480
DTP vaccine
Number of doses (regardless of 
age)
·· ·· ·· <0·0001
0 480 (12·5%) 201 (11·8%) 249 (5·0%) ··
1–2 1086 (28·3%) 484 (28·4%) 1060 (21·1%) ··
≥3 2267 (59·1%) 1017 (60·0%) 3708 (73·9%) ··
Fully vaccinated for age†
Age <1 year 1724 (70·3%) 751 (69·5%) 2258 (81·0%) <0·0001
Age ≥ 1 year 1264 (91·5%) 566 (91·1%) 2083 (93·5%) 0·1407
PCV
Number of doses (regardless of 
age)
·· ·· ·· 0·0014
0 1690 (43·8%) 701 (40·8%) 2404 (47·9%) ··
1–2 1021 (26·4%) 480 (28·0%) 1056 (21·0%) ··
≥3 1151 (29·8%) 536 (31·2%) 1561 (31·1%) ··
Fully vaccinated for age‡
Age <1 year 1226 (49·7%) 566 (52·0%) 1384 (49·6%) 0·0004
Age ≥1 year 640 (45·9%) 291 (46·3%) 867 (38·8%) 0·7019
Full vaccination for measles§ 1453 (86·8%) 646 (85·3%) 2459 (90·6%) 0·0135
Mid-upper arm circumference 
<11·5 cm¶
171 (7·4%) 93 (8·8%) 29 (0·8%) <0·0001
Weight-for-age Z score ·· ·· ·· <0·0001
Severe (< –3) 631 (15·9%) 338 (19·2%) 196 (3·9%) ··
Moderate (≥ –3 to < –2) 754 (19·0%) 361 (20·5%) 515 (10·1%) ··
Normal (≥ –2) 2584 (65·1%) 1062 (60·3%) 4368 (86·0%) ··
Antibiotic activity detected in 
serum
918 (24·5%) 425 (25·3%) 85 (1·8%) <0·0001
Previous exposure to antibiotics|| 1530 (38·9%) 704 (40·1%) 85 (1·7%) <0·0001
Median duration of illness (days) 3·0 (2·0–5·0) 3·0 (2·0–5·0) ·· ··
Very severe pneumonia 1279 (32·1%) 519 (29·3%) ·· ··
Wheeze on auscultation 1340 (33·9%) 555 (31·7%) ·· ··
Tachypnoea 3256 (82·4%) 1492 (85·3%) ·· ··
Hypoxaemia 1423 (35·8%) 748 (42·3%) ·· ··
Oxygen use at admission** 1243 (37·4%) 671 (43·9%) ·· ··
Temperature ≥38·0°C 1213 (30·5%) 591 (33·5%) ·· ··
CRP ≥40 mg/L 925 (27·6%) 526 (34·9%) ·· ··
Elevated WBC count 1620 (43·4%) 793 (47·8%) ·· ··
(Table 2 continues on next page)
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tuberculosis cultures to 98·6% for blood cultures) were 
collected and tested (figure 1); reasons for missing 
specimens included specimens not collected because of 
physician discretion or contraindication (particularly 
for induced sputum), specimens lost in transport, 
and parental refusal.16 Cases (251 [5·9%] of 4232) and 
controls (17 [0·3%] of 5119) with HIV infection were 
otherwise excluded from analyses in this report, leaving 
3981 (94·1%) of 4232 cases and 5102 (99·7%) of 
5119 con trols categorised as without HIV infection 
(figure 1, appendix). The primary analysis further 
restricted cases to those with positive chest x­rays 
(1769 [52·1%] of 3396 who had an interpretable x­ray; 
table 2, 3 appendix). The descriptive laboratory analysis 
and the primary aetiology analysis excluded an additional 
two cases and 27 controls missing all microbiology test 
results. The secondary all­case aetiology analysis 
(ie, regardless of x­ray findings) included 3968 cases and 
5075 controls with at least one micro biology test result 
(figure 1); of the 3972 cases with at least one test result, 
four cases who tested positive for measles by NP­OP 
PCR (all without an infiltrate on their chest x­rays) were 
excluded from the all­case analysis.
Demographic and clinical characteristics are 
presented in table 2, table 3, and the appendix. Cases 
were unevenly distributed across the seven sites; of all 
cases with a positive chest x­ray (1769), Thailand made 
up the lowest percentage (5·5%), whereas South Africa 
made up the highest (24·6%; appendix) of the seven 
countries. For every site except Thailand, more than 
75% of cases with a positive x­ray were younger than 
24 months, with the majority being younger than 
12 months (appendix). Controls were older than cases 
in The Gambia, Mali, South Africa, and Dhaka 
(Bangladesh) sites (p<0·020; appendix). The proportion 
of cases with very severe pneumonia was lowest in 
Bangladesh and The Gambia and highest in Mali and 
Kenya (p<0·0001; table 2, 3, appendix). 30­day case­
fatality ratio of cases with a positive x­ray was 6·4% (114 
of 1769 cases), which varied markedly by site (p<0·0001) 
and was higher in cases with very severe pneumonia 
(13·3% of 519 very severe cases without HIV infection 
and with a positive x­ray; range by site 3·7–28·2%) than 
in cases with severe pneumonia (3·6% of 1250 severe 
cases without HIV infection and with a positive x­ray; 
range by site 0·5–9·7%; appendix).
Clinical characteristics at admission of cases with 
a positive chest x­ray varied substantially by site (table 2, 3, 
appendix), particularly for wheezing (range by site 
10·6–97·3%), fever (9·7–58·9%), hypoxaemia 
(10·0–75·8%), and oxygen administration (5·5–90·1%; 
p<0·0001 for all). It should be noted that the South African 
site, at an altitude of 1600 m above sea level, had a 
standard clinical practice to administer supplemental 
oxygen at admission and often before recording oxygen 
saturation for all children admitted to hospital with 
a diagnosis of severe pneumonia. Additionally, Mali 
oxygen administration data were excluded from analysis 
because of inadequate standardisation of data recording. 
Tachypnoea was commonly observed at all sites 
(85·3% of cases). Malnutrition, defined as WHO 
weight­for­age Z score37 lower than –2, was found in 
39·7% of cases with a positive x­ray and without HIV 
infection, with significant variability by site (p<0·0001 for 
all); malnutrition was more common in cases than in 
controls at all sites (appendix). The prevalence of any 
All cases Cases with a 
positive x-ray
Controls p value
(Continued from previous page)
Chest x-ray findings
Positive 1769 (44·4%) 1769 (100%) ·· ··
Consolidation 841 (21·1%) 841 (47·5%) ·· ··
Other infiltrate 928 (23·3%) 928 (52·5%) ·· ··
Negative 1627 (40·9%) ·· ·· ··
Uninterpretable 351 (8·8%) ·· ·· ··
Missing 234 (5·9%) ·· ·· ··
Blood culture volume, mL††
1 to <2 1649 (48·7%) 753 (51·4%) ·· ··
≥2 to <3 1313 (38·8%) 537 (36·7%) ·· ··
≥3 425 (12·6%) 175 (12·0%) ·· ··
Died in hospital or within 30 days 
of admission
292 (7·3%) 114 (6·4%) ·· ··
Died in hospital 251 (6·3%) 95 (5·4%) ·· ··
Died post discharge, within 
30 days of admission‡‡
41 (1·0%) 19 (1·1%) ·· ··
Missing 30-day vital status 346 (8·7%) 146 (8·3%) ·· ··
Data are n (%) or median (IQR). Positive cases are those with a positive chest x-ray. p values obtained from logistic 
regression models adjusted for age in months (all variables expect age category) and site for cases with a positive x-ray 
versus controls. During the study, pneumococcal conjugate vaccine (PCV) was in routine use in Kenya (introduced 
February, 2011), The Gambia (August, 2009), Mali (March, 2011), and South Africa (April, 2009); PCV was introduced 
in Zambia in July, 2013 (Lusaka), 3 months before the end of study enrolment. Duration of illness was defined as 
duration (in days) of cough, wheeze, fever, or difficulty breathing, whichever was longest. Tachypnoea was defined as 
60 or more breaths per min (<2 months), 50 or more breaths per min (2–11 months), and 40 or more breaths per min 
(12–59 months). Hypoxaemia was defined as oxygen saturation lower than 92% (or <90% for sites at elevation above 
1200 m: Zambia and South Africa), or supplemental oxygen use if a room air oxygen saturation reading was not 
available; a room air oxygen saturation reading was available for 3514 (88·3%) children; the South African site, at an 
altitude of 1600 m above sea level, had a standard clinical practice to administer supplemental oxygen for all children 
admitted to hospital with a diagnosis of severe pneumonia. Elevated white blood cell (WBC) count was defined as 
greater than 15 × 109 cells per L for children aged 1–11 months and greater than 13 × 109 cells per L for children aged 
12–59 months. CRP=C-reactive protein. *Restricted to endemic sites (Kenya, Gambia, Mali, and Zambia). †For children 
younger than 1 year, full vaccination was defined as having received at least one dose and being up to date for age on 
the basis of the child’s age at enrolment, doses received, and country schedule (allowing a 4-week window for each 
dose); for children aged 1 year or older, full vaccination was defined as having received three or more doses. ‡For 
children younger than 1 year, full vaccination was defined as having received at least one dose and being up to date for 
age on the basis of the child’s age at enrolment, doses received, and country schedule (allowing a 4-week window for 
each dose); for children aged 1 year or older in all sites except Kenya, full vaccination was defined as having received 
three or more doses; for children older than 1 year in Kenya (which introduced PCV with catch-up campaign), 
full vaccination was defined as having received three or more doses, two doses if given at least 8 weeks apart and the 
child was older than 1 year of age at first dose, and one dose if the child was older than 2 years at any dose or at 
introduction. §Data restricted to those age-eligible; at least one dose was restricted to children older than 10 months 
(>10·5 months in Bangladesh). ¶Restricted to children aged 6 months or older. ||Defined as serum bioassay positive 
(cases and controls), antibiotics administered at the referral facility, or antibiotic administration before the collection 
of whole blood specimens at the study facility (cases only); restricted to children with blood culture (cases only) or 
whole blood (cases or controls) collected. **Data was recorded in the Mali site on the basis of time at presentation, 
not time at admission, as was done at all other sites; Mali is excluded from the all site summary. ††13·7% of cases with 
a blood culture collected were missing blood culture volume data.29 ‡‡Restricted to children discharged alive who had 
vital status data obtained 21 days or longer after admission.
Table 2: Demographic and clinical characteristics of cases without HIV infection and controls for all sites
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respiratory symptom among controls without HIV 
infection was 23·6% (range by site 5·4–41·2%, appendix).
Previous exposure to antibiotics varied by site and case 
or control status, as did coverage with vaccines against 
pertussis, Hib, S pneumoniae, and measles (appendix; 
p<0·050 for all). Enrolment of cases varied by season at 
all sites, except in Mali and Zambia (appendix).
Blood cultures were positive for a pathogen in 56 (3·2%) 
of 1749 cases with positive chest x­rays and available blood 
cultures (percentage range by site 1·0–5·0%; figure 2, 
appendix). Isolation rates did not vary significantly by age 
strata (p=0·21), but did vary by case severity (p=0·014) and 
were 45% lower among cases with previous antibiotic 
exposure or with blood volume lower than 1·0 mL 
(appendix).28 The bacterial species most commonly isolated 
from blood cultures was S pneumoniae (19 [34%] of 
56 positive blood cultures); however, no pneumococcal 
isolates were cultured from sites in South Africa, Thailand, 
or Bangladesh. Although not part of the core methods, 
South Africa had two blood cultures that were flagged as 
positive and tested positive for pneumococcal antigen, but 
were negative for pneumococcal culture (appendix).
M tuberculosis was cultured from 24 (1·5%) of 
1571  cases with positive x­rays (23 from induced sputum 
and one from gastric aspirate; appendix). 11 (29%) of 
37 lung aspirates and 12 (80%) of 15 pleural fluid speci­
mens tested by culture, PCR, or both were positive for a 
pathogen; bacterial pathogens (most often S pneumoniae 
[lung aspirate] and S aureus [pleural fluid]) were more 
commonly detected (in 23 cases) than viral pathogens 
(three cases), and all viral pathogens were co­detected 
with bacteria (table 4, appendix). Multiple pathogens 
were observed in six (55%) of 11 lung aspirates that 
yielded at least one pathogen by culture or PCR.
None of the ten cases with positive chest x­rays who met 
the clinical screening definition for measles testing were 
positive for measles (appendix). Legionella longbeachae 
infection was identified in one case, a 19­month­old 
Zambian child without HIV infection with very severe 
pneumonia, in both NP­OP and induced sputum speci­
mens by multiplex PCR and confirmatory uniplex PCR.
Almost all cases (3867 [98·9%] of 3910) and controls 
(4886 [98·0%] of 4984) had at least one pathogen detected 
(ie, ignoring density threshold) by PCR in the NP­OP 
specimen; most cases (2313 [59·2%]) and controls 
(2667 [53·5%]) had four or more patho gens detected 
(appendix). The mean number of potential pathogens 
detected in NP­OP specimens was 3·8 (SD 1·5) among 
cases and 3·6 (SD 1·5) among controls. Among cases 
with multiple pathogens detected in NP­OP specimens, 
3219 (88·4%) of 3642 had both viral and bacterial 
detections; no pathogen was commonly found alone 
(appendix). In cases with a positive chest x­ray, the most 
common bacteria detected in NP­OP specimens were 
S pneumoniae (1265 [72·8%] of 1737), M catarrhalis 
(1153 [66·4%]), H influenzae (1004 [57·8%]), and S aureus 
(268 [15·4%]), whereas cytomegalovirus (890 [51·2%]) 
and RSV (506 [29·1%]) were the most common viruses 
(appendix). Influenza virus was rarely detected (influenza 
A 62 [3·6%]; influenza B 18 [1·0%]; influenza C 10 [0·6%]). 
S pneumoniae was more commonly detected in controls 
(3846 [77·2%] of 4984) than in cases with a positive chest 
x­ray (p=0·0001). After applying PCR density thresholds 
that best distinguished cases from controls,24,25 the 
proportion of positive results in cases with a positive 
x­ray changed for S pneumoniae (from 72·8% to 13·5%), 
H influenzae (from 57·8% to 29·5%), P jirovecii (from 
8·9% to 4·3%), and cytomegalo virus (from 51·2% to 
22·7%). This changed the rank order of most commonly 
detected bacteria in the NP­OP specimens to M catarrhalis, 
H influenzae, S aureus, and S pneumoniae (appendix). 
Compared with controls, having a positive chest x­ray 
in cases was significantly associated with the presence of 
15 different pathogens in NP­OP specimens (figure 3). 
The adjusted ORs for NP­OP PCR results ranged widely 
across pathogens, with RSV (OR 14·0, 95% CI 11·4–17·1), 
parainfluenza 1 (7·7, 4·6–13·0), and human meta­
pneumovirus A or B (6·3, 4·8–8·2) having the highest 
adjusted ORs, followed by influenza A (3·6, 2·4–5·3) 
and Bordetella pertussis (3·3, 1·6–7·2); parainfluenza 1, 
influenza A, and B pertussis were infrequently detected in 
cases (figure 3, appendix). M catarrhalis was the only 
pathogen significantly negatively associated with case 
status (OR 0·6, 95% CI 0·5–0·7). We observed only minor 
changes in the magnitude and direction of the ORs after 
removing the adjustment for detection of the other 
pathogens (appendix).
Whole blood PCR was positive for S pneumoniae in 
cases with a positive x­ray (128 [7·6%] of 1676) at nearly 
the same prevalence as in controls (255 [5·3%] of 4779; 
OR 1·2, 95% CI 1·0–1·6); after applying a PCR density 
threshold (≥2·2 log10 copies per mL) to enhance differ­
entiation of cases and controls,26,27 prevalence was 
91 (5·4%) of 1676 cases with a positive chest x­ray versus 
144 (3·0%) of 4779 controls (1·6, 1·2–2·1; appendix).
Integrating the microbiology results from the multiple 
specimens among the 1767 cases with a positive chest x­ray 
and the 5075 controls, we estimated that more disease was 
due to viral pathogens (61·4%, 95% CrI 57·3–65·6) than to 
bacterial pathogens (other than M tuberculosis; 27·3%, 
23·3–31·6); the remaining aetiological fractions were 
attributed to M tuberculosis, Candida spp, P jirovecii, and 
causes not otherwise specified (figure 4A, appendix). RSV 
was the most common cause (31·1%, 95% CrI 28·4–34·2), 
and other common pathogens (each accounting for 5% or 
more of the aetiological distribution) included human 
rhinovirus, HMPV A or B, human parainfluenza virus 
(types 1–4 combined), S pneumoniae, M tuberculosis, and 
H influenzae. Unknown causes (NOS category) accounted 
for 1·8% (95% CrI 0·2–4·5) of the pneumonia aetiology 
distribution. The fraction of pneumonia attributable to 
pathogens targeted by currently licensed vaccines (Hib, 
vaccine­serotype S pneumoniae, pertussis, M tuberculosis, 
and influenza A or B) was 14·0% (11·3–17·0).
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Some pathogens differed in their aetiological fraction 
by age strata. B pertussis, parainfluenza type 3, S aureus, 
P jirovecii, and RSV had a greater aetiological fraction in 
children younger than 1 year than in those aged 1 year or 
older, whereas parechovirus–enterovirus, parainfluenza 
type 1, rhinovirus, and S pneumoniae were more common 
causes in children aged 1 year or older than in those 
younger than 1 year (figure 4B; appendix). We found 
seven pathogens in the top ten pathogens of both 
age strata (RSV, rhinovirus, HMPV, parainfluenza, 
S pneumoniae, M tuberculosis, and H influenzae). The 
aetiological distribution by finer age strata is provided in 
the appendix. We observed differences in aetiological 
fraction by pneumonia severity for RSV, S aureus, 
S pneumoniae, parainfluenza type 3, and all viral causes 
combined (figure 4C, appendix).
In analyses of all cases regardless of chest x­ray 
findings compared with cases with a positive x­ray, a 
greater aetiological fraction was attributed to rhinovirus 
(11·4% in all cases vs 7·5% in cases with a positive 
x­ray), parechovirus–enterovirus (4·6% vs 1·6%) and 
non­fermenting Gram­negative bacteria (2·8% vs 0·9%) 
in all cases, but otherwise, the analyses did not differ 
substantively (appendix). Aetiology by chest x­ray find­
ings will be reported in a separate manuscript.
The site­specific aetiology results standardised for 
age and severity of the ten focus pathogens showed 
consistency across the sites for most pathogens (figure 5, 
appendix), including for influenza, which did not exceed 
3% in any site except Zambia (6·1%). Exceptions to this 
consistency included the following: rhinovirus was sub­
stantially more common in Bangladesh (29·7%) and 
Kenya (12·9%); H influenzae was extremely uncommon 
in Bangladesh (0·7%); H influenzae type b in Zambia 
(3·4%) and Mali (4·2%) and non­type b H influenzae in 
South Africa (10·0%) were dispro portionately higher 
than in other sites; and S pneumoniae, both vaccine­types 
and non­vaccine­types, was higher in The Gambia (15·1%) 
and Mali (17·4%) than in other sites. The fraction of 
cases attributed to bacteria was lower in Bangladesh 
(10·4%) and Kenya (17·5%) than in other sites (range 
32·7–37·6). M tuberculosis had a larger aetiological 
fraction in Zambia, The Gambia, Thailand, and South 
Africa (6·4–10·2) than in other sites (<3%). The NOS 
contribution was 2% or less in all sites except Thailand 
(7·4%). The results stan dardised for age and severity 
(appendix) did not differ from the primary, non­
standardised, site­specific results (ie, based on the mix of 
cases enrolled at each site).
The cumulative aetiological fraction of the standardised 
and site­specific ten most common pathogens accounted 
for between 79·0% and 90·0% of the aetiological fraction at 
every site (figure 6). By contrast, the cumulative aetiological 
fraction of the ten focus pathogens ranged by site from 
55·1% to 86·6%, reflecting heterogeneity across the sites 
in the rank order of each pathogen (appendix). The 
distribution of the individual case aetiological probability 
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for each pathogen, for the case­specific leading pathogen, 
and for any virus by site are provided in the appendix.
Sensitivity analyses were done to assess the effect of 
the assumptions of PIA model sensitivity and aetiology 
priors on the aetiology findings. Lowering and narrowing 
the pneumococcal blood culture sensitivity prior, or 
increasing its aetiology prior, had little effect on the 
S pneumoniae aetiology estimate, probably because of the 
strength of evidence regarding S pneumoniae from the 
other measurements (NP­OP PCR and whole blood PCR; 
appendix). Increasing the aetiology prior of NOS from 
3% (base case) to 25% resulted in an increase in the NOS 
aetiology estimate from lower than 8% at all sites to 
8–25% across sites (appendix).
Discussion
The principal finding of the PERCH study was that, 
in low­income and low­middle­income settings with 
wide spread uptake of Hib vaccine and PCV, viruses, 
especially RSV, were the predominant cause of pneu­
monia requiring hospital admission in children younger 
than 5 years at all sites, but bacteria continued to cause 
from a quarter to a third of all cases. In each site, a small 
number of pathogens accounted for most cases admitted 
to hospital with radiographically confirmed pneumonia; 
the ten most common pathogens at a given site accounted 
for 79% or more of cases of disease at that site. 
Furthermore, most cases at every site were caused by a 
handful of pathogens that were commonly found in all 
sites. Nonetheless, the relative contribution of these 
pathogens varied by age and, to a lesser degree, by 
severity of the disease.
Approximately half of children admitted to hospital 
defined by WHO as having severe or very severe 
pneumonia had an infiltrate on chest x­rays, and among 
these cases, clinical characteristics varied substantially 
across all sites, including case severity at presentation, 
presence of wheeze, and case­fatality ratios. Nevertheless, 
we found little variability in the pathogens commonly 
detected from body fluid specimens of cases across study 
sites, except for the low recovery of bacteria from blood 
specimens in the Asian sites, or the pathogens accounting 
for the majority of aetiology distribution.
RSV was the dominant pathogen in all sites, 
accounting for 31·1% of the aetiology distribution, more 
than three times greater than the next leading pathogen. 
RSV was notable not only for its frequent detection in 
the NP­OP of cases with a positive chest x­ray, but also 
for its uncommon detection in controls, making it one 
of a few pathogens (including parainfluenza 1 and 
HMPV) for which detection had high predictive value 
for aetiological attribution. RSV was a common 
pathogen across age strata and pneumonia severities, 
although the aetiological fraction was notably higher in 
infants than in older children. The predominance of 
RSV emphasises its importance as a prevention and 
therapeutic target. In the past decade, pneumonia 
aetiology studies29,38 in the USA and South Africa and 
the GABRIEL multisite study39 also identified RSV as an 
important target.
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Figure 2: Blood culture results by study site in cases with positive chest x-ray and without HIV infection
Enterobacteriaceae includes Escherichia coli, Enterobacter spp, and Klebsiella spp, excluding mixed Gram-negative rods. Other streptopcocci and enterococci include 
Streptococcus pyogenes and Enterococcus faecium. Mixed label includes Salmonella spp and other streptopcocci and enterococci. Contaminants, including those organisms 
deemed to be contaminants after clinical review, were excluded from the analysis. Figure is restricted to cases with available blood culture results. The numbers on the 
top of the bars refer to the total number of positive blood cultures. Two of the cases positive for pneumococcus in Kenya were pneumococcal conjugate vaccine (PCV) 
13-type but not PCV10-type (serotypes 19A and 6A). Antibiotic pretreatment (defined as having a positive serum bioassay result, antibiotics administered at the referral 
facility, or antibiotic administration before whole-blood specimen collection at the study facility) varied by site: The Gambia (composite 10·6%, bioassay 7·6%), 
Mali (22·4%, 17·1%), Kenya (35·1%, 10·0%), Zambia (92·2%, 25·3%), South Africa (57·2%, 54·2%), Bangladesh (24·6%, 21·6%), and Thailand (30·6%, 19·4%).
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The contribution of parainfluenza viruses and HMPV to 
the aetiological distribution varied little by age strata or 
disease severity but did vary by site. We recorded a low 
prevalence (<5%) of influenza A or B in all sites and the 
aetiological contribution of influenza A or B did not exceed 
3% in any site except Zambia (6·1%). Influenza circulation 
varies annually, and the 2 years of enrolment in the 
PERCH study might have been low circulation years.
Of the tested pathogens, human rhinovirus was 
associated with the most geographical heterogeneity in 
aetiological fraction, ranging from 30% in Bangladesh 
and 13% in Kenya, to less than 2% in Zambia, The 
Gambia, and Mali. Human rhinovirus predominance 
in Kenya was not explained by an overrepresentation 
of respiratory infection seasons (three compared with 
two seasons in all other African sites; appendix), on the 
basis of an analysis of the Kenya data that excluded the 
third respiratory season (data not shown). Although well 
described as a cause of upper respiratory tract infection, 
the role of human rhinovirus as a cause of pneumonia is 
uncertain.40–42 It is possible that human rhinovirus, as 
several other respiratory viruses, might be incorrectly 
attributed as the true cause of pneumonia despite all 
methodological and analytical efforts to address this. 
This general limitation extends beyond this study to 
most case­control studies for pneumonia aetiology, 
leading to an exaggeration of the contribution of viruses 
to pneumonia when the primary specimen used to assess 
causality is from the upper respiratory tract. However, 
the OR and the significant association with wheeze (data 
not shown) argues against this.
For bacteria that commonly colonise the upper 
respiratory tract, such as S pneumoniae and H influenzae, 
the inferential role of NP­OP PCR for estimating aetiology 
in a case­control study has inherent uncertainties. To 
mitigate the risk of underestimating the attributable 
aetiology of these bacterial pathogens, analyses incor­
porated pathogen density measures from the NP­OP 
specimens to distinguish cases from controls, adjustment 
for antibiotic exposure that lowers detection in the NP­OP 
PCR, and blood PCR for S pneumoniae. Additionally, for 
these and all bacterial pathogens, we directly sampled 
from the lung (albeit in few cases), optimised and adjusted 
for the volume of blood for culture, accounted for the 
effect of previous antibiotic exposure on the sensitivity of 
bacterial pathogen detection for blood cultures, and 
accounted for the low sensitivity of blood cultures.
About 3% of cases in the PERCH study had a non­
contaminant organisms isolated from blood culture. 
S pneumoniae was the most common isolate, consistent 
with other childhood pneumonia aetiology studies.29,38 
Although we attempted to improve identification of cases 
with true pneumococcal pneumonia using whole blood 
PCR,26,27 the specificity was poor because prevalence was 
similar between cases and controls (aOR 1·2); this 
improved somewhat when bacterial load was considered 
(aOR 1·6). Perhaps the poor specificity of blood PCR is 
due to low level seeding, swallowed sputum, or gastro­
intestinal tract absorption of pneumococcal antigens 
from common colonisation with S pneumoniae in the 
nasopharynx.43 This mechanism is also believed to be the 
source of poor pneumococcal urine antigen specificity.44 
Despite the high prevalence of pneumococcal NP­OP 
colonisation among children in every site,25 the 
prevalence of positive blood PCR for S pneumoniae was 
lower in Asian sites26 and in the Zambia site, which had 
the highest prevalence of antibiotic pretreatment. Neither 
Culture PCR Culture, PCR, or 
both
Lung aspirate
Cases with available results (n) 37 25 37
Any positive* 5 (13·5%) 9 (36·0%) 11 (29·7%)
Streptococcus pneumoniae† 5 (13·5%) 6 (24·0%) 8 (21·6%)
Haemophilus influenzae non-b‡ 1 (2·7%) 4 (16·0%) 4 (10·8%)
Chlamydophila pneumoniae 0 1 (4·0%) 1 (2·7%)
Moraxella catarrhalis 0 4 (16·0%) 4 (10·8%)
Human metapneumovirus NA 1 (4·0%) 1 (2·7%)
Adenovirus NA 1 (4·0%) 1 (2·7%)
Combinations
S pneumoniae + H influenzae 1 (2·7%)§ 1 (4·0%) 1 (2·7%)
S pneumoniae + M catarrhalis 0 2 (8·0%) 2 (5·4%)
Adenovirus + C pneumoniae NA 1 (4·0%) 1 (2·7%)
H influenzae + M catarrhalis 
+ S pneumoniae
NA 1 (4·0%) 1 (2·7%)§
H influenzae + M catarrhalis + human 
metapneumovirus
NA 1 (4·0%) 1 (2·7%)
Negative 32 (86·5%) 16 (64·0%) 26 (70·3%)
Pleural fluid
Cases with available results (n) 15 12 15
Any positive* 9 (60·0%) 7 (58·3%) 12 (80·0%)
S pneumoniae† 1 (6·7%) 4 (33·3%) 5 (33·3%)¶
Staphylococcus aureus 7 (46·7%) 4 (33·3%) 7 (46·7%)
Escherichia coli 1 (6·7%) 0 1 (6·7%)
Streptococcus group F 1 (6·7%) 0 1 (6·7%)
Human bocavirus NA 1 (8·3%) 1 (6·7%)
Combinations
E coli + streptococcus group F 1 (6·7%) NA 1 (6·7%)
S aureus + human bocavirus NA 1 (8·3%) 1 (6·7%)
S pneumoniae + S aureus 0 0 1 (6·7%)¶
Negative 6 (40·0%) 5 (41·7%) 3 (20·0%)
Data are n (%). Results were restricted to specimens obtained within 3 days of enrolment and to those pathogens 
determined by the clinical review team to be non-contaminants. NA=not applicable. *Total number of cases with a 
positive culture result; does not equal the number of organisms identified because some cases appear in multiple rows 
(any positive and in combination). †For S pneumoniae in lung aspirates, PCV13 types were identified in three cases, 
non-PCV13 types were identified in two cases, and three cases did not have serotyping available (PCR-positive alone); 
for S pneumoniae in pleural fluid, PCV13 type was identified in one case and four cases did not have serotyping available 
(positive result only for PCR test, antigen test, or both). ‡One case positive for H influenzae by lung aspirate was 
missing serotyping data for the culture isolate but was negative for H influenzae type b by lung aspirate PCR. §This case 
was positive for S pneumoniae and H influenzae by lung aspirate culture and positive for H influenzae, M catarrhalis, and 
S pneumoniae by lung aspirate PCR; therefore, it is reported twice in this table. ¶Three cases were positive in pleural 
fluid for S pneumoniae by antigen testing; two of these were also positive for S pneumoniae in culture, PCR, or both, 
and one was positive only for S pneumoniae in antigen testing.
Table 4: Organisms identified by culture and PCR of lung aspirate or pleural fluid specimens in cases with 
a positive chest x-ray and without HIV infection
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the Asian sites nor the South Africa site had a positive 
blood culture for S pneumoniae, unlike the other four 
African sites. We investigated the site performance of 
blood collection and culture and found no methodological 
explanation for the inability to isolate S pneumoniae from 
blood cultures at these three sites, nor for the lower 
prevalence of positive pneumococcal results in the Asian 
sites compared with that of other sites. However, the 
South Africa site had two blood culture samples that 
were alarm positive, culture negative, with pneumococci 
in chains detected on Gram stain, and Binax positive, 
and all three sites isolated pneumococci from blood in 
patients who were not enrolled in the PERCH study 
during the same period. Antibiotic treatment before 
specimen collection is known to influence the isolation 
of bacteria from blood and NP, as we have previously 
described,25,28 but does not substantially influence 
pneumococcal detection by whole blood PCR.26,27 The 
prevalence of antibiotic pretreatment was particularly 
high in Zambia (92%), South Africa (57%), and Kenya 
(35%); this was accounted for, as described previously, by 
reducing the sensitivity.
There were reasons to expect that, in our study, there 
would be a lower burden of pneumococcal disease than 
in earlier studies. By design, sites with PCV in routine 
use were targeted for participation in the PERCH study 
(all except Zambia, Thailand, and Bangladesh used 
PCV), which could have reduced the pneumococcal 
pneumonia disease burden by approximately 70% at 
those sites, if the serotype distribution matched that of 
invasive pneumococcal disease.45 The low pneumococcal 
aetiological attribution is supported by the low prevalence 
of radiographic consolidation that has been shown to 
be associated with bacterial pneumonia,46–48 which 
comprised only 25% of all PERCH cases and half of the 
cases with a positive chest x­ray.  Furthermore, 60% of 
cases in the PERCH study were younger than 1 year, with 
many younger than 6 months, a group often excluded 
from the analyses of clinical trials of pneumococcal 
vaccine that partly formed the basis for our expectations 
about pneumococcal burden. Economic development 
and improved access to care might also have reduced 
hospital admissions for pneumococcal pneumonia 
through effective early outpatient treatment. In some 
sites, such as Thailand, the absence of any detected cases 
of pneumococcal bacteraemia might simply reflect low 
enrolment numbers, given that invasive pneumococcal 
disease has been observed at this site in other studies.49–51
Among other vaccine­preventable pathogens, 
M tuberculosis burden varied by site, accounting for 
6–10% of the aetiology in four sites (The Gambia, Zambia, 
South Africa, and Thailand), but less than 3% elsewhere. 
M tuberculosis was rarely cultured from induced sputum 
or gastric aspirates and, in the South Africa site, testing 
more than one specimen increased the yield.52 The 
sensitivity of M tuberculosis culture is low when testing a 
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Figure 3: Nasopharyngeal-oropharyngeal (NP-OP) pathogen prevalence* and adjusted odds ratios (OR) in cases with positive chest x-ray and without HIV infection and in controls without 
HIV infection
Pathogens are ordered alphabetically among bacteria, followed by viruses and fungi. ORs adjusted for age (months), site, and presence of other pathogens detected by NP-OP PCR, but not adjusted for 
previous antibiotic use, which is known to influence bacterial positivity. *Prevalence defined by use of NP-OP PCR density thresholds for four pathogens: Pneumocystis jirovecii, 4 log10 copies per mL; 
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PCV=pneumococcal conjugate vaccine.
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single induced sputum specimen (30%) and remains low 
even when multiple samples were taken from children 
with pulmonary tuberculosis;53 this was accounted for in 
the aetiology model. Perhaps owing to high vaccination 
rates, B pertussis was rarely identified but, when present, 
was most often found in children younger than 
12 months. Detection of B pertussis by PCR of NP­OP 
specimens was highly predictive of case status, with very 
few positives identified in controls.54 We saw few cases 
that were clinically compatible with measles, therefore it 
is unlikely that we missed many measles­related cases of 
pneumonia, highlighting the efforts of measles control at 
the sites during the study. Hib was an uncommon cause 
for pneumonia in our study and was less com mon than 
non­type b H influenzae. The longstanding use of Hib 
vaccine in several study sites could have accounted for the 
low contribution of Hib to the aetiological distribution. 
However, the two sites where the contribution of Hib 
exceeded the contribution of non­b H influenzae (Mali 
and Zambia) did not have the lowest Hib vaccination 
rates. Thailand was the only site not using Hib vaccine; 
the reason for the small contribution of Hib to pneumonia 
aetiology in Thailand is unclear, but might relate to access 
to outpatient antibiotics.
P jirovecii is a prominent cause of pneumonia among 
children with HIV infection. The PERCH study has 
shown that it is also a relevant cause of pneumonia in a 
subset of children without HIV infection. Among cases, 
those who had P jirovecii detected in the NP­OP 
specimens were more likely than other cases to be 
younger than 6 months and malnourished. To the best 
of our knowledge, the single case of legionellosis (in the 
Zambia site) that we identified is the first reported case 
of childhood infection due to L longbeachae in Africa.
The aetiological contribution of non­tested pathogens 
(ie, the NOS category) was approximately 2% in the all­
site analysis. Sensitivity analyses that assumed a higher 
fraction for the NOS category (aetiology prior set at 
25% vs 3%) concluded that the NOS category would 
probably not account for more than 15% of cases across 
the sites, except in Thailand (25%). This emphasises 
that strong evidence exists for the aetiological 
contribution of pathogens tested for in our study, unless 
there is substantial confounding of the true cause by 
these pathogens. Because the value chosen for the 
aetiology prior influences the fraction attributed to the 
NOS category, our analysis cannot be used to estimate 
precisely the size of the NOS category. However, it does 
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infection from all PERCH sites combined
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aetiological fraction to its SE. Of two identical aetiological fraction estimates, the estimate associated with a larger symbol is more informed by the data than the 
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streptococci and enterococci includes Streptococcus pyogenes and Enterococcus faecium. Non-fermentative Gram-negative rods (NFGNR) includes Acinetobacter spp 
and Pseudomonas spp. Enterobacteriaceae includes Escherichia coli, Enterobacter spp, and Klebsiella spp, excluding mixed Gram-negative rods. Pathogens that were 
estimated at the subspecies level, but grouped to the species level for display include parainfluenza virus type 1, 2, 3 and 4; Streptococcus pneumoniae PCV 13 and 
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affirm that NOS accounts for a small fraction of 
pneumonia causes.
The contribution of NP­OP data for assessing aetiolog­
ical probability depends on differences in frequency of 
detection between cases and controls. The validity of 
NP­OP infection as a source of aetiological inference for a 
selected group of pneumonia pathogens is supported by 
the finding that clear distinctions in prevalence by case or 
control status were found consistently across sites. 
However, NP­OP specimens provide little inferential value 
to the cause of pneumonia at the individual case level, 
except for a small group of pathogens, such as RSV and 
B pertussis. Collection of induced sputum added little value 
beyond that of the NP­OP specimen, despite the high 
quality of the lower respiratory tract specimens.30,32 For 
those pathogens with NP­OP OR lower than 1, ruling out 
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Figure 5: Site-specific aetiology results for ten focus pathogens in cases with a positive chest x-ray and without HIV infection
The size of the symbol is scaled on the basis of the ratio of the estimated aetiological fraction to its SE. Of two identical aetiological fraction estimates, the estimate 
associated with a larger symbol is more informed by the data than the priors. Positive chest x-rays defined as consolidation or other infiltrate on the x-ray. 
Graph restricted to the ten focus pathogens from the all-site analysis, which include those with aetiology estimate higher than 5% (n=7) or higher than 2% that were of 
epidemiological interest (defined as treatable by antibiotics [Pneumocystis jirovecii and Staphylococcus aureus] or having an available vaccine [influenza virus]). 
The 95% credibility intervals for the aetiological fractions of these three pathogens overlap with some non-focus pathogens, hence our use of the term focus pathogen 
rather than labelling these ten as the most common pathogens. Other pathogens category represents the sum of the aetiological fraction for all remaining pathogens 
tested for, but not presented in this figure. Site-specific results were standardised to the following case mix: 40% younger than 1 year with severe pneumonia, 
20% younger than 1 year with very severe pneumonia, 30% aged 1 year or older with severe pneumonia, and 10% aged 1 year or older with very severe pneumonia. 
Pathogens estimated at the subspecies level, but grouped to the species level for display include parainfluenza virus types 1, 2, 3, and 4; Streptococcus pneumoniae 
PCV13 and S pneumoniae non-PCV13 types; Haemophilus influenzae type b and H influenzae non-type b; and influenza virus A, B, and C. Exact figures are given in the 
appendix. NOS=not otherwise specified (ie, pathogens we did not test for). *The summary for bacteria excludes Mycobacterium tuberculosis.
Articles
18 www.thelancet.com   Published online June 27, 2019   http://dx.doi.org/10.1016/S0140-6736(19)30721-4
their role in the causal chain was not possible with this 
study design; probe or longitudinal study designs are 
needed to better understand the contribution of these 
pathogens to pneumonia aetiology and better explore the 
sequence from NP­OP infection to lung infection. Despite 
their limitations, NP­OP specimens remain of substantial 
importance for pneumonia aetiology studies because they 
are easily collected, can be subjected to molecular 
diagnostic testing, and can provide valid information about 
infection of certain pathogens in the respiratory tract.
Four sites (The Gambia, South Africa, Mali, and 
Bangladesh) included lung aspirate specimen collection 
as part of the study protocol. Because of the clinical 
criteria for specimen collection (ie, cases with anterior, 
large, and right­sided consolidation), hesitation from 
clinicians and families, and delays in ethical approvals 
and training at some sites, only 37 (6·8%) of 545 cases 
with radiographic consolidation enrolled at these four 
sites had a lung aspirate specimen collected. Pathogen 
detection from lung aspirates was lower (29% overall, 
41% when both culture and PCR were undertaken) than 
that reported in previous studies, possibly because the 
timing of lung aspirates occurred after antibiotic 
administration.55 Pleural fluid specimens, included in 
the study protocol in all sites at the discretion of the 
treating clinicians, were only available from 15 (8%) of 
180 cases in whom at least one standardised chest x­ray 
reader identified pleural fluid; however, a pathogen was 
detected in 80% of these specimens. Bacteria were more 
com monly detected on these specimens than viruses, 
with the most common being S pneumoniae in lung 
aspirates and S aureus in pleural fluid. These specimens, 
although most directly reflective of the true cause of 
pneumonia, were collected in a highly selected group of 
cases and the results are unlikely to be generalisable.
Clinical characteristics and case outcomes varied 
substantially by site. The high variation in wheezing 
prevalence among cases, especially the extremely 
high prevalence in Bangladesh, might be related to poor 
air quality, infection, or underlying propensity for 
bronchospasm in the children presenting for care.56–58 
Sites also differed in the mix of case severity, which 
might reflect underlying host factors (eg, nutritional 
status), other concurrent illnesses (eg, malaria), or 
patient propensity for seeking care and ability to access to 
care. Because pathogen findings differed by case severity, 
it is possible that the stratification of cases on finer or 
differently defined severity indicators might control for 
some confounding by site. Case­fatality ratios varied by 
site, reflecting differences in case severity and clinical 
care. Among all cases who died in the 30 days after 
hospital admission, only a small proportion of deaths 
(41 [14%] of 292) occurred after discharge. This is similar 
to the proportion of mortality (16% of deaths) observed to 
occur after discharge in a study of severe pneumonia 
requiring hospital admission in children younger than 5 
years in Kilifi,59 but contrasts with the substantial 
proportion of mortality (74% of deaths) observed to occur 
in the 90 days after enrolment for diarrhoeal illness in 
the GEMS study,60 although those children were followed 
for a longer period.
We did not obtain chest x­rays from a small proportion 
of cases (6%, n=234), many (33%) because of death soon 
after enrolment, limiting the representation of 
microbiological findings in immediately fatal cases in the 
primary analysis. Among cases with a chest x­ray, 
53% had either a normal or uninterpretable finding; by 
design, the WHO clinical pneumonia case definitions are 
highly sensitive, but non­specific. We focused on the 
epidemiological and laboratory characteristics of cases 
with pneumonia with a positive x­ray to enhance the 
specificity of the clinical case definition for pneumonia, 
recognising that this might introduce bias by excluding 
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Figure 6: Cumulative contribution of site-specific ten most common pathogens in cases with a positive chest 
x-ray and without HIV infection
Positive chest x-rays defined as consolidation or other infiltrate on the x-ray. Site-specific results were standardised 
to the following case mix: 40% younger than 1 year with severe pneumonia, 20% younger than 1 year with very 
severe pneumonia, 30% aged 1 year or older with severe pneumonia, and 10% aged 1 year or older with very severe 
pneumonia. Ranks correspond to the site-specific rank from the top ten pathogens of each site; the pathogen 
corresponding to each rank varies by site (see inset panel). Other strep category includes Streptococcus pyogenes 
and Enterococcus faecium. Non-fermentative Gram-negative rods (NFGNR) includes Acinetobacter spp and 
Pseudomonas spp. Enterobacteriaceae category (Entrb) includes Escherichia coli, Enterobacteriaceae spp, and 
Klebsiella spp, excluding mixed Gram-negative rods. Pathogens estimated at the subspecies level, but grouped to 
the species level for display include parainfluenza virus types 1, 2, 3, and 4; Streptococcus pneumoniae PCV13 and 
S pneumoniae non-PCV13 types; Haemophilus influenzae type b and H influenzae non-type b; and influenza virus A, 
B, and C. Boca=human bocavirus. Cand sp=Candida spp. CMV=cytomegalovirus. Flu=influenza virus A, B and C. 
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catarrhalis. NOS=not otherwise specified (ie, pathogens we did not test for). P jirov=Pneumocystis jirovecii. 
Para=parainfluenza virus type 1, 2, 3 and 4. PV-EV=parechovirus–enterovirus. Rhino=human rhinovirus. 
RSV=respiratory syncytial virus A or B. S aur=Staphylococcus aureus. S pneu=S pneumoniae. Salm sp=Salmonella spp.
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cases with pneumonia whose x­ray findings lagged 
behind the clinical findings or cases with lower tract 
disease caused by pathogens who did not have chest x­ray 
infiltrates (eg, pertussis). We assessed this bias by 
providing analyses of all cases, regardless of x­ray 
findings, and observed little difference in the findings. 
Notably, among cases without a positive chest x­ray, 
26% either had a missing or uninterpretable x­ray.
We did the PERCH study over a 24­month period at 
each site to obtain more reliable data on annual seasonality 
patterns and to increase the probability of detecting 
pathogens that exhibit multi­year epidemic cycles. We 
were unlikely to miss seasonal outbreaks; however, 
some pathogens (eg, B pertussis, influenza subtypes, 
parainfluenza viruses, and Mycoplasma pneumoniae) have 
periodicities that are longer than 24 months and, therefore, 
we might have observed quiescent periods.61–64
Among the ten focus pathogens of our study, a subset 
(HMPV, parainfluenza, S pneumoniae, human rhinovirus, 
H influenzae, and M tuberculosis) differed in their impor­
tance across sites. The estimated contributions of some 
pathogens varied by age strata (RSV, pertussis, parainflu­
enza types 1 and 3, P jirovecii, S aureus, S pneumoniae, 
parechovirus­enterovirus, and rhinovirus) and by disease 
severity (all viral causes combined, RSV, S aureus, 
S pneumoniae, and parainfluenza type 3), which might 
have implications for treatment guideline revisions. 
Because preventive measures against current pathogens 
are increasingly implemented, the proportional aetiological 
distribution will continue to change over time.
The PERCH study results can be compared with other 
childhood pneumonia aetiology studies.29,39,65,66 The 
multisite BOSTID study66,67 from the 1980s, an important 
historical reference, detected viruses and bacteria from 
upper respiratory specimens and bacterial antigens from 
urine specimens and found high prevalence of RSV, 
S pneumoniae, and Hib. The PERCH study differed 
substantially from BOSTID in study design through the 
inclusion of controls, in strict standardisation of case 
definitions and methods, and in the breadth and 
types of laboratory testing. The multicountry GABRIEL 
pneumonia case­control aetiology study,65 done in low­
income settings and published in 2017, also highlighted 
RSV as a major causative pathogen. However, the 
aetiological attribution for RSV was substantially lower 
in the GABRIEL study than in the PERCH study 
(18% vs 31%).65 This discordance appears mainly 
attributable to differences in the prevalence of RSV in 
GABRIEL (20% of cases) compared with that in the 
PERCH study (29% of cases), rather than a result of 
different analytical approaches. Study design and 
methodological differences probably affected the rate of 
RSV detection; specifically, the age distribution of cases 
enrolled in GABRIEL was older than that of cases in 
PERCH, and GABRIEL controls were enrolled from 
facilities, rather than from the community. Although 
S pneumoniae detection in NP specimens in cases was 
similar between the two studies (68% in GABRIEL vs 
73% in PERCH [any detection]), the control prevalence 
was considerably lower in GABRIEL (48% vs 77%), 
resulting in a high OR and attributable fraction in the 
GABRIEL study. The difference in pneumococcal 
findings between the PERCH and GABRIEL studies is 
unlikely to lie in the case definitions used, which were 
similar between studies. Instead, notable differences 
existed in PCV use (nearly absent in GABRIEL, but 
widely used in PERCH) and in control eligibility (facility­
based recruitment and no respiratory symptoms in 
GABRIEL vs community controls regardless of respi­
ratory symptoms, if not case­defining, in PERCH). 
Additionally, the proportion of cases and controls who 
had detection of both viruses and bacteria was sub­
stantially higher in PERCH (83·5% cases and 75·8% of 
controls had mixed bacterial­viral detection) than in 
GABRIEL (59·6% cases and 36·1% controls), suggesting 
that other differences in the selection of participants or 
in clinical or laboratory methods might have also 
contributed. In the EPIC study38 of childhood pneumonia 
aetiology from the USA, RSV and human rhinovirus 
were the most commonly detected pathogens from 
the upper respiratory tract among young children 
hospitalised with radiographic pneumonia, and a larger 
proportion of children had no pathogen detected 
compared with that of PERCH (18·9% in EPIC vs 0·9% 
in PERCH). In the South African Drakenstein case­
control substudy29 of pneumonia aetiology (using the 
same multiplex PCR assay as PERCH), cases were 
predominantly children with non­severe pneumonia, 
managed in outpatient settings, and with a median age 
of 5 months. Nevertheless, a range of pathogens similar 
to that of the PERCH study was associated with 
pneumonia case status, but the prevalence of influenza 
was higher. Unlike the PERCH study of severe 
pneumonia with hospital admission, the Drakenstein 
substudy found that cytomegalovirus, bocavirus, and 
adenovirus were associated with case status.29
Our study has several limitations, particularly related to 
viral pathogens as confounders of pneumonia aetiology, to 
the copathogen interpretation, and to bacterial aetiology. 
Our descriptive analysis underscored limitations inherent 
to nearly every pneumonia aetiology study—multiple 
specimens, multiple tests with varying sensitivity and 
specificity, and the absence of an established and 
principled method to integrate the results in a single 
aetiology analysis—and justifies the novel analytical 
approach we have taken. As in all case­control studies, 
residual confounding cannot be excluded. Despite 
matching controls by community of residence, age, and 
season of cases, there are likely to be factors that influence 
nasopharyngeal infection and independently influence 
infection with significant lung pathogens (eg, crowding); 
this could overestimate the role of viruses and 
underestimate the role of bacteria. The PIA model 
integrates the multiple observed laboratory results, 
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acknowledging the inherent error in laboratory meas­
urements, the reduced sensitivity of assays because of 
previous antibiotic use or low blood culture volume, and 
the indirect nature of data obtained from sampling 
body fluids distant from the lung. The model assumes 
each case has a primary pathogen as the cause and does 
not attempt to estimate whether specific pathogen 
combinations are necessary for pneumonia. This 
approach has been described in detail elsewhere9 and has 
been contrasted with the standard attributable fraction 
method. The PIA model includes assumptions on the 
sensitivity of laboratory measures and aetiology priors, 
each with a range provided. The validity of the assumptions 
regarding sensitivity is limited by the availability of data 
on diagnostic test performance. Despite the potential 
misspecification of these assumptions, sensitivity analyses 
showed that the aetiology results were robust to changes 
in these values, except the aetiology prior for NOS.9 
Furthermore, the inherent ability of an observational 
study to accurately define the contribution of bacteria to 
pneumonia is uncertain. To advance this problem will 
require better diagnostics (such as discriminating PCR in 
blood samples or other pathogen­specific, infection­
specific biomarkers), specimens other than the NP­OP 
swabs (such as lung aspirates, which are very challenging 
to obtain), and the sampling of patients before they have 
had antibiotics, which, in the era of community case 
management, is increasingly unlikely. A vaccine probe 
study is the optimal way to reveal the contribution of a 
pathogen to pneumonia,68 but this can only be undertaken 
for one or two pathogens at a time. Finally, the all­site 
PERCH study pneumonia aetiological distribution 
reflected estimates of the distribution of cases with 
pneumonia who were admitted to a hospital, outside of 
the neonatal period, across the PERCH study sites during 
the period of observation. We recognise that pneumonia is 
an important illness in neonates. Because there was a 
sister study, ANISA,69 assessing the causes of neonatal 
disease during the same period, the PERCH study focused 
on children outside the neonatal period.
The results from the PERCH study should not be 
extrapolated as the global aetiological distribution of 
severe childhood pneumonia or interpreted as the aetio­
logical distribution at the national level for each of the 
participating sites. At the time of study initiation (2011), 
88% of countries eligible for programmes of Gavi, the 
Vaccine Alliance, were using Hib vaccine and 21% were 
using PCV in their routine immunisation programmes.70 
However, the PERCH study was intentionally designed to 
reflect the aetiology in the setting of high PCV and Hib 
vaccine use. By 2020, these vaccines are expected to be 
used in 100% (Hib vaccine) and 93% (PCV vaccine) of 
Gavi­eligible countries.70 Furthermore, the aetiological 
distribution among the cases does not necessarily reflect 
the aetiological distribution among pneumonia deaths, 
especially in children who died in the community without 
the provision of curative care efforts.
The PERCH study was designed to update the evidence 
base on causes of serious pneumonia with use of the most 
advanced clinical, microbiological, and analytical methods, 
deployed across geographically and epidemiologically 
diverse study sites in Africa and south Asia, where the 
pneumonia burden is greatest. Beyond comparing the 
clinical and microbiological findings of cases and controls, 
as has traditionally been done in aetiology studies, we 
have used a novel analytical method to overcome some of 
the limitations of this traditional approach and estimate 
the aetiology distribution, with 95% CrI, in both the 
population and each individual. Previously, infectious 
aetiology studies were unable to integrate the results from 
multiple specimen types for multiple pathogens.
Our results highlight the consistency of the pneumonia 
aetiology findings across sites, disease severity, and age 
strata, providing evidence to target the handful of 
pathogens that are consistently identified as important 
for prevention and treatment. RSV is the most common 
cause of serious pneumonia with hospital admission in 
these settings and should be a target for dedicated 
prevention and treatment efforts. Bacterial pathogens 
cumulatively cause a substantial proportion of disease 
and, because they are treatable and commonly fatal, 
should remain as targets for early access to appropriate 
supportive and curative treatment. The PERCH study 
estimated that 61% of pneumonia requiring hospital 
admission in children younger than 5 years and without 
HIV infection had a primary viral cause; however, we 
cannot firmly exclude the presence of bacterial co­
infection, as discussed above. Nevertheless, this finding 
strengthens the need to adjust pneumonia treatment 
algorithms to emphasise supportive care and identify 
children for whom antibiotics are unlikely to be 
therapeutic, thereby reducing the pressure for 
antimicrobial resistance. Future pneumonia research 
needs to address the conundrum of multiple pathogens 
and the sequence of their role in pneumonia 
pathogenesis. The findings from the PERCH study 
should prompt additional investments in pneumonia 
prevention, testing, triage, and treatment and should 
encourage the use of innovative design and analyses in 
aetiology studies, especially those that can further assess 
pneumonia as a multipathogen disease.
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